TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Incidence of Surgical Site Events (SSEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Rate of decline in neuropsychological and behavioral composites
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cortical volume on structural MRI
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Increase of leaks/gaps with fluorescein extrusion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Clavien-Dindo postoperative morbidity (POM) score
Endpoint domain: Adverse events/effects
Primary endpoint: blood loss during hepatectomy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Mean Femoral Broach Time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Overall Costs
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Microbiome composition
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Microbiome metabolic signatures
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Metabolic products of fructan metabolism
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of clinically relevant new findings or worsening of a pre-existing findings as assessed by Hematology
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Number of clinically relevant new findings or worsening of a pre-existing findings as assessed by Clinical chemistry
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of clinically relevant new findings or worsening of a pre-existing findings as assessed by urinalysis report
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Calcineurin inhibitors drug levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants Alive at Time of Last Follow-up
Endpoint domain: Mortality/survival
Primary endpoint: Number of Participants With no Major Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: renal remission
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: renal response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Self Reported Relapse Rate
Endpoint domain: Adverse events/effects
Primary endpoint: Efficacy of anakinra
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: VRE number change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Intraocular Pressure (IOP) in the Study Eye
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Gene expression evaluated by measuring mRNA via RT-PCR
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma PAI-1 content
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Endotoxemia score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Percentage of patients benefiting from early stop of antibiotic treatment
Endpoint domain: Adverse events/effects
Primary endpoint: US-CRP blood levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: IL-6 blood levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: lymphocyte activity Th1 Th2 Th17 Treg
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Chorio-retinal depth and morphology
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC calculated to the end of a dosing interval (tau) at steady-state (AUCtau)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Severity Index of plaque changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Change in breast tumor proliferation index (Ki67)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Change in proportion of patients achieving tumoral complete cell cycle arrest
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Post Root Canal Treatment Pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: incidence rate of skin lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: DPV concentration in plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: DPV concentration in cervicovaginal fluid
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: DPV concentration in cervical tissue
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety comparison of the two extended duration DPV VRs
Endpoint domain: Adverse events/effects
Primary endpoint: Plasma sodium
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Achievement of operational tolerance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety of high IV iron dosing regimen
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Participants With Viral Load of Less Than 400 Copies/mL
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Percentage of Participants With Viral Load of Less Than 50 Copies/mL
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Post-treatment ADHD Symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Perception of managing depression and anxiety in heart failure
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in Weekly Mean of 24-hour Average Pain Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of arrested caries lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to Resolution of Influenza Symptoms and Fever
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Auditory Event-related potentials
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Visual Event-related potentials
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Identification of a dysrhythmia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Average weight loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Quantification of D-dimer in the circulating blood
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Quantification of Fibrin monomer in the circulating blood
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Quantification of Tissue Factor-Dependent Procoagulant Activity (MP-TF) in the circulating blood
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Weight Service Utilization
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Patient Weight Outcomes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Supported Employment Utilization
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Patient Employment Outcomes
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Changes in Montgomery-Asberg Depression Rating Scale (MADRS)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Changes in Perceived Deficits Questionnaire - 5 items (PDQ-5)
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change from Numeric Rating Scale (NRS) of Pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Weight Patterns (gain and loss)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Complete/nearly complete resolution of the Infantile Hemangioma
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Percentage of treatment areas with >75% reduction in lesion count
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of treatment areas with 100% cure rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline in the Canadian Occupational Performance Measure
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Patient Posas Score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Anhedonia/Activation
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Changes in blood insulin and C-peptide
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Changes in anthropometrics
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction of NIV failure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Independent Living Skills Survey (ILSS)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Time to bacteremia clearance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Change in Bronchitis Severity Score (BSS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Area under the plasma concentration-time curve from time 0 to infinity (AUC0→∞)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum drug concentration in plasma at steady state (Cpss)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Half life (t½) of drug in plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: N-terminal pro-B type natriuretic peptide, troponin-I and D-dimer levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Airway transverse diameter
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Cumulative incidence of local control
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pattern of failure (local or metastatic)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of freezing of gait episodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: 2-Year Progression-Free Survival Rate
Endpoint domain: Mortality/survival
Primary endpoint: Number of Participants With and Without 50% Reduction in metHb Level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Brain Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Stress Hormone Response (Cortisol to ACTH Ratio)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Concentration of γ-OH-Acr-dGuo
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in whole body insulin sensitivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Muscle mitochondrial function
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of falls/near fall experiences
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Extent and quality of fluorescence in the tumour core
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Composition of the fecal bacterial and fungal microbiota
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma Concentration-Time Curve (AUC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Antiplatelet therapy discontinuation
Endpoint domain: Adverse events/effects
Primary endpoint: Change in Balance Tests score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Spatial Orientation Tests score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in voxel-wise morphometric brain analysis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in peak power output
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in sub-maximal arm-ergometry
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Geometric Means Titers (GMTs) of Antibodies Against Each Dengue Virus Serotype Strains
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of Participants With Antibody Titers Greater Than or Equal to (>=)10 (1/Dilution) Against Each Dengue Virus Serotype Strains
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Response Rate According to RECIST
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: success rate of Critical Flicker Frequency (CFF) Procedure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time spent on tracheostomy-collar (off mechanical ventilation)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: SPF Value of the teat product
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Wechsler Adult Intelligence Scale (WAIS)-III Working Memory Index
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Breastfeeding at six months
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Vascular event or vascular intervention
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Recurrence of active Clostridium difficile associated diarrhea
Endpoint domain: Adverse events/effects
Primary endpoint: New cases of Clostridium difficile associated diarrhea
Endpoint domain: Adverse events/effects
Primary endpoint: 5-Year Survival Rate
Endpoint domain: Mortality/survival
Primary endpoint: Number of Participants With Device-related Serious Adverse Events (SAEs) Through Three and Five Years
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With Therapy-related Serious Adverse Events (SAEs) Through Three and Five Years
Endpoint domain: Adverse events/effects
Primary endpoint: Glucose measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Increase in urinary concentrations of TIMP-2 and IGFBP7
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Cumulative incidence of acute Graft versus Host Disease (GvHD) of grade II to IV
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: 1.3 BDG in peritoneal exudate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Clinical picture of viral respiratory and gastrointestinal infection
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Breast Tissue Physiology
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical response defined by a ≥ 1 point decrease from baseline in the Modified Rankin Scale (mRS) at Day 91 post treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical response defined by a ≥ 1 point decrease from baseline in the Modified Rankin Scale (mRS) at Day 181 post treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Change in Intra-ocular Pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Eyes With Uncorrected High Contrast Distance Visual Acuity of 20/40 or Better
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Preservation of Manifest Best Corrected High Contrast Distance Visual Acuity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Eyes With Manifest Best-corrected Distance Photopic Visual Acuity Decrease of 2 or More Lines
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to Mobilization
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: attentional network activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: FMISO-PET derived hypoxic volumes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage change in FMISO-PET SUVmax and uptake volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Facility-based birth coverage
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Incidence rate of progression from stage 2 ROP to more severe stage ROP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ophthalmological outcomes
Primary endpoint: Plasma concentrations of propranolol at the steady state
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ankle-brachial systolic pressure index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: transcutaneous oxygen value (mm Torr)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: quality of life (questionnaires)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Measurement performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Asthma Patients - Exacerbations: Clinical
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Asthma Patients - Exacerbations: Severe
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in POSAS Patient Scale Total Sum of Scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: MRI inflammatory changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: SLE activity scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: intermittent claudication distance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Improvement of Bone Mass
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Number of Subjects Meeting the Toxicity Threshold for dAXP Concentration
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Subjects Meeting the Optimal Threshold for ADA Activity
Endpoint domain: Adverse events/effects
Primary endpoint: Changes in physical fitness prior to surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in immunological function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Oropharyngeal dysphagia screening
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: postoperative early recurrence
Endpoint domain: Mortality/survival
Primary endpoint: Asymptomatic lower-extremity DVT
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Changes in plasma LDL-C concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in rate of achievement of the category-specific target LDL-C level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Volume of in vivo ablation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: cortical morphology
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: target gene characteristics
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: scale scores
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Volume change after LVA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement of action myoclonus
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Pharmacokinetics of naloxegol
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Presence or absence of tympanic membrane perforation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ear outcomes
Primary endpoint: Blood and urinary biomarkers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Number of Participants That Experienced Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Change in Cortisol AUCi
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Change Heart Rate Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in Modified Mallet Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Absolute Change in Right Ventricular Ejection Fraction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Disability-free survival rate
Endpoint domain: Mortality/survival
Primary endpoint: incidence of GVHD
Endpoint domain: Adverse events/effects
Primary endpoint: 3 Month Progression Free Survival (PFS)
Endpoint domain: Mortality/survival
Primary endpoint: Immune cell profile and kinetics
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes